Effect of Covid-19 vaccine on some immunological salivary biomarkers (sIgA and Interleukine-17)
DOI:
https://doi.org/10.32007/jfacmedbagdad.2039Keywords:
SARS-CoV-2, Covid-19, Vaccination, Pfizer (BNT162b2), Secretory (sIgA), IL-17Abstract
Background: The most widely used vaccination against SARS-associated coronavirus (SARS-CoV-2) is the Pfizer vaccine, which provides protection against this virus. However, its ability to safeguard the oral cavity is unclear, and neither are the exact immunological biomarker levels it activates.
Aim of the study: To investigate the possibility that Pfizer vaccination protects the oral cavity against Covid-19.
Patients and Methods: The study group consisted of a total of 70 subjects (30 as the control group They were followed up before being vaccinated as non-vaccinated (maybe previously infected or non-infected or recovered) and 40 participants followed up three weeks after the first dose and one week after the second vaccination. All saliva samples were collected from the individuals in the current study at the medical city hospital in Baghdad from September 2021 to July 2022. The salivary biomarkers sIgA and IL-17 were detected by enzyme-linked immunosorbent assay (ELISA) kits.
Result: Secretory IgA levels showed a highly significant difference (p0.05) in the followed-up group after the first vaccination compared to the non-vaccinated group (controls), however, a non-significant difference in its level was found in the followed-up group after the first vaccination compared to after the second vaccination. In contrast to healthy controls, non-vaccinated participants had greater salivary IL-17 levels. Followed-up participants’ IL-17 levels did not change significantly after the first and second vaccines (P>0.05).
Conclusion: The Pfizer vaccine had a minor impact on sIgA because mRNA vaccines protect systemically more than salivary. Nevertheless, the Pfizer vaccine raises IL-17 levels after the first and second doses without triggering cytokine syndrome.
Downloads
References
Nejabi M, Noor N, Raufi N, Essar M, Ehsan E, Shah J, et al. Tongue ulcer in a patient with COVID-19: a case presentation. BMC Oral Health 2021;21:1-5.
Farook FF, Nuzaim MNM, Ababneh KT, Alshammari A & Alkadi L. COVID-19 pandemic: Oral health challenges and recommendations European journal of dentistry. 2020; 14(S 01), S165-S170.
Sauer K, & Harris T. An effective COVID-19 vaccine needs to engage T cells Frontiers in Immunology. 2020; 2371.
Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB & Prado EO. SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates npj Vaccines. 2021; 6(1), 1-17.
Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Antibodies to combat viral infections: development strategies and progress Nature Reviews Drug Discovery. 2022; 21(9), 676-696
Al-Atrooshi BA, Al-Rawi AS. 2007. Oral halitosis and oral hygiene practices among dental students. Journal of Baghdad college of dentistry; 19(1), 72-76.
Rashad S, El-Chaghaby G. Algae Bioactive Constituents and Possible Role During COVID-19 Pandemic (A review) Iraqi Journal of Pharmaceutical Sciences (P-ISSN: 1683-3597, E-ISSN: 2521-3512). 2021; 30(2), 16-22 https://doiorg/1031351/vol30iss2pp16-22.
Khamees SI & Mohammad AN. Evaluation of inorganic ions and enzymes levels in saliva of patients with chronic periodontitis and healthy subjects. Therapy. 2012; 6, 7.
Khanday AMUD, Khan QR, Rabani ST. Ensemble Approach for Detecting COVID-19 Propaganda on Online Social Networks Iraqi Journal of Science. 2022; 63(10), 4488–4498 https://doiorg/1024996/ijs2022631033.
l-Azzawi AKJ and Al-Zubaidi, AK. 2014. The effect of various endodontic irrigants on the sealing ability of biodentine and other root perforation repair materials: in vitro study. J. Baghdad Coll. Dent; 26, 1-8.
Adham ZS, & Al-Ghurabi BH. Prevalence of viral co-infection among COVID-19 cases in association disease severity and oral hygiene Journal of Baghdad College of Dentistry. 2021; 33(3), 1–8https://doiorg/1026477/jbcdv33i32947.
Matuchansky C. Mucosal immunity to SARS-CoV-2: a clinically relevant key to deciphering natural and vaccine-induced defences Clinical Microbiology and Infection, 2021; 27(12), 1724-1726.
Isaza-Guzmán DM, Cardona-Vélez N, Gaviria-Correa DE, Martínez-Pabón MC, Castaño-Granada MC, Tobón-Arroyave SI. Association study between salivary levels of interferon (IFN)-gamma, interleukin (IL)-17, IL-21, and IL-22 with chronic periodontitis Archives of oral biology. 2015; 60(1), 91-99.
Mills KH. IL-17 and IL-17-producing cells in protection versus pathology Nature Reviews Immunology. 2022; 1-17.
Shibabaw T. Inflammatory cytokine: IL-17A signaling pathway in patients present with COVID-19 and current treatment strategy Journal of inflammation research. 2020; 13, 673.
Kareem HH, Al-Ghurabi BH, Albadri C. Molecular Detection of Porphyromonas gingivalis in COVID-19 Patients Journal of Baghdad College of Dentistry. 2022; 34(2), 52–61 https://doiorg/1026477/jbcdv34i23145.
Kar S, Devnath P, Emran TB, Tallei TE, Mitra S, Dhama K. Oral and intranasal vaccines against SARS‐CoV‐2: Current progress, prospects, advantages, and challenges Immunity, Inflammation and Disease. 2022; 10(4), e604.
Azzi L, Dalla Gasperina D, Veronesi G, Shallak M, Ietto G, Iovino D, et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients EBioMedicine. 2022 75, 103788.
Tu MK, Chiang SH, Bender RA, Wong DT, Strom CM. The kinetics of COVID-19 vaccine response in a community-vaccinated population The Journal of Immunology. 2022; 208(4), 819-826.
Ehrenberg AJ, Moehle EA, Brook CE, Doudna Cate AH, Witkowsky LB, Sachdeva R. IGI SARS-CoV-2 Testing Consortium (2021) Launching a saliva-based SARS-CoV-2 surveillance testing program on a university campus PloS one. 2021; 16(5), e0251296.
Tsukinoki K, Yamamoto T, Handa K, Iwamiya M, Saruta J, Ino S, et al. Detection of cross-reactive immunoglobulin A against the severe acute respiratory syndrome-coronavirus-2 spike 1 subunit in saliva PloS one. 2021; 16(11), e0249979.
Dellière S, Salmona M, Minier M, Gabassi A, Alanio A, Le Goff J, et al. Evaluation of the COVID-19 IgG/IgM rapid test from orient gene biotech Journal of clinical microbiology. 2020; 58(8), e01233-20.
Estadilla CDS, Uyheng J, de Lara-Tuprio EP, Teng TR, Macalalag JMR, Estuar MRJE. Impact of vaccine supplies and delays on optimal control of the COVID-19 pandemic: mapping interventions for the Philippines Infectious Diseases of Poverty. 2021; 10(04), 46-59.
Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in hospitalized patients with COVID-19 Journal of the American Society of Nephrology. 2021; 32(1), 151-160.
Jensen A, Stromme M, Moyassari S, Chadha AS, Tartaglia MC, Szoeke C, et al. COVID-19 vaccines: Considering sex differences in efficacy and safety Contemporary Clinical Trials. 2022; 106700.
De Magistris MT. Mucosal delivery of vaccine antigens and its advantages in pediatrics Advanced drug delivery reviews. 2006; 58(1), 52-67.
Darwich A, Pozzi C, Fornasa G, Lizier M, Azzolini E, Spadoni I, et al. BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection? EMBO molecular medicine. 2022; 14(5), e15326.
Sheikh-Mohamed S, Isho B, Chao GY, Zuo M, Cohen C, Lustig Y, et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection Mucosal immunology. 2022; 1-10.
Mohamed SS, Chao GY, Isho B, Zuo M, Nahass GR, Salomon-Shulman R E, et al. A mucosal antibody response is induced by intra-muscular SARS-CoV-2 mRNA vaccination medRxiv. 2021.
Sano, K., Bhavsar, D., Singh, G., Floda, D., Srivastava, K., Gleason, C., ... & Krammer, F. (2022). SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals. Nature Communications. 13(1); 5135.
Sundar S, Ramadoss, R., Shanmugham, R, Ananda padmanabhan LT, Paneerselvam S, Ramani P & Karobari MI. 2022. Salivary Antibody Response of COVID-19 in Vaccinated and Unvaccinated Young Adult Populations. Vaccines. 10(11); 1819.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China Clinical immunology. 2020; 214, 108393.
Ong SWX, Fong SW, Young BE, Chan YH, Lee B, Amrun SN, et al. (2021, June) Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients In Open forum infectious diseases. 2021; (Vol 8, No 6, p ofab156) US: Oxford University Press.
Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge Journal of virology. 2011, 85(23), 12201-12215.
Kimura A & Kishimoto T. IL‐6: regulator of Treg/Th17 balance European journal of immunology. 2010; 40(7), 1830-1835
Rokni M, Hamblin MR, Rezaei N. Cytokines and COVID-19: friends or foes? Human vaccines & immunotherapeutics. 2020; 16(10), 2363-2365.
Jin W & Dong C. IL-17 cytokines in immunity and inflammation Emerging microbes & infections. 2013; 2(1), 1-5.
Martonik D, Parfieniuk-Kowerda A, Rogalska M, Flisiak R. The role of Th17 response in COVID-19 Cells. 2021; 10(6), 1550.
Lin Y, Slight SR, & Khader SA (2010, March) Th17 cytokines and vaccine-induced immunity In Seminars in immunopathology (Vol 32, No 1, pp 79-90) Springer-Verlag
Merino KM, Jazwinski SM, Rout N. Th17-type immunity and inflammation of aging Aging (Albany NY). 2021; 13(10), 13378.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Dhuha Ali, Ghada Taha
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Creative Commons Attribution 4.0 International license..
